Tracks
Related Products
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
PARTNERING WITH PATIENTS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS USING AN ORAL PRESCRIPTION THERAPY
Dr. Bincy Abraham and Gabriella McCarty, NP, will discuss proactive patient involvement in shared decision-making by incorporating a case-based approach within the clinical overview of an oral prescription therapy for moderate-to-severe ulcerative colitis…
IBD Complications
This session will examine the outcomes of a spectrum of IBD related complications including colon cancer. It will also examine cost and efficient care delivery…
Emerging Strategies for the Management of Complicated IBD
This session will examine a variety of alternate strategies for the management of complicated IBD including stem cell transplantation and novel therapies…
